Peter Jørgensen: The Impact of Biosimilars on Danish Patients

June 10, 2019

Peter Jørgensen, director of the Industrial Association for Generic and Biosimilar Medicines, Denmark, explains how Danish patients are benefitting from biosimilars.

Transcript

I think the Danish patients are being impacted in several ways. Firstly, more patients have now access to biological treatment than what they did before; as we all know, biologic medicines have been very, very expensive. They have also been very efficient, but they have been very expensive in Denmark. Last year, of 25 products being used in Danish hospitals, 24 of them were biologics. Of course they have been expensive, but now when you add biosimilars into the market, more patients are being treated, and they're being treated earlier.

At the same time, this would also free up money in other places of the system. We all know we are having a lot of new cancer products coming in. They are, I assume, efficient, but for certain, very expensive.

The fact that you can save a lot of money by using biosimilars will, as I say, free up money that means that other patients, cancer patients, for instance, can benefit because you can start to use new treatment at an earlier point in time without jeopardizing the total health care budget.